Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Feb 15;2012(2):CD006659.
doi: 10.1002/14651858.CD006659.pub3.

Carnitine supplementation for inborn errors of metabolism

Mona Nasser  1 , Hoda Javaheri, Zbys Fedorowicz, Zaman Noorani
Affiliations

Carnitine supplementation for inborn errors of metabolism

Mona Nasser et al. Cochrane Database Syst Rev. .

Abstract

Background: Inborn errors of metabolism are genetic conditions which can lead to abnormalities in the synthesis and metabolism of proteins, carbohydrates, or fats. It has been proposed that in some instances carnitine supplementation should be provided to infants with a suspected metabolic disease as an interim measure, particularly whilst awaiting test results. Carnitine supplementation is used in the treatment of primary carnitine deficiency, and also where the deficiency is a secondary complication of several inborn errors of metabolism, such as organic acidaemias and fatty acid oxidation defects in children and adults.

Objectives: To assess the effectiveness and safety of carnitine supplementation in the treatment of inborn errors of metabolism.

Search methods: We searched the Cystic Fibrosis and Genetic Disorders Group's Inborn Errors of Metabolism Trials Register, the Cochrane Central Register of Controlled Trials (The Cochrane Library 2007, Issue 4) and MEDLINE via Ovid (1950 to July week 4 2007), LILACS (15/05/2008) and Iranmedex (15/05/2008) and also the reference lists of retrieved articles.Date of most recent search of the Group's Inborn Errors of Metabolism Register: 27 October 2011.

Selection criteria: Randomised controlled trials and quasi-randomised controlled trials comparing carnitine supplementation (in different dose, frequency, or duration) versus placebo in children and adults diagnosed with an inborn error of metabolism.

Data collection and analysis: Two authors independently screened and assessed the eligibility of the identified trials.

Main results: No trials were included in the review.

Authors' conclusions: There are no published or ongoing randomised controlled clinical trials relevant to this review question. Therefore, in the absence of any high level evidence, clinicians should base their decisions on clinical experience and in conjunction with preferences of the individual where appropriate. This does not mean that carnitine is ineffective or should not be used in any inborn error of metabolism. However, given the lack of evidence both on the effectiveness and safety of carnitine and on the necessary dose and frequency to be prescribed, the current prescribing practice should continue to be observed and monitored with care until further evidence is available. Methodologically sound trials, reported according to the Consolidated Standards of Reporting Trials (CONSORT) statement, are required. It should be considered whether placebo-controlled trials in potentially lethal diseases, e.g. carnitine transporter disorder or glutaric aciduria type I, are ethical.

PubMed Disclaimer

Conflict of interest statement

There are no financial conflicts of interest and the review authors declare that they do not have any associations with any parties who may have vested interests in the results of this review.

Update of

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies excluded from this review

Angelini 1987 {published data only}
    1. Angelini C, Trevisan C, Isaya G, Pegolo G, Vergani L. Clinical varieties of carnitine and carnitine palmitoyltransferase deficiency. Clinical Biochemistry 1987;29(1):1‐7. - PubMed
Baric 1998 {published data only}
    1. Baric I, Zschocke J, Christensen E, Duran M, Goodman SI, Leonard JV, et al. Diagnosis and management of glutaric aciduria type I. Journal of Inherited Metabolic Disease 1998;21(4):326‐40. - PubMed
Bhuiyan 1992 {published data only}
    1. Bhuiyan AK, Jackson S, Turnbull DM, Aynsley‐Green A, Leonard JV, Bartlett K. The measurement of carnitine and acyl‐carnitines: application to the investigation of patients with suspected inherited disorders of mitochondrial fatty acid oxidation. Clinica Chimica Acta 1992;207(3):185‐204. - PubMed
Bjugstad 2000 {published data only}
    1. Bjugstad KB, Goodman SI, Freed CR. Age at symptom onset predicts severity of motor impairment and clinical outcome of glutaric acidemia type 1. Journal of Pediatrics 2000;137(5):681‐6. - PubMed
Bohles 1991 {published data only}
    1. Bohles H, Ullrich K, Endres W, Behbehani AW, Wendel U. Inadequate iron availability as a possible cause of low serum carnitine concentrations in patients with phenylketonuria. European Journal of Pediatrics 1991;150(6):425‐8. - PubMed
Bowyer 1989 {published data only}
    1. Bowyer BA, Fleming CR, Haymond MW, Miles JM. L‐carnitine: effect of intravenous administration on fuel homeostasis in normal subjects and home‐parenteral‐nutrition patients with low plasma carnitine concentrations. American Journal of Clinical Nutrition 1989;49(4):618‐23. - PubMed
Chazot 2003 {published data only}
    1. Chazot C, Blanc C, Hurot J M, Charra B, Jean G, Laurent G. Nutritional effects of carnitine supplementation in hemodialysis patients. Clinical Nephrology 2006;59(1):24‐30. - PubMed
Cruciani 2004 {published data only}
    1. Cruciani RA, Dvorkin E, Homel P, Culliney B, Malamud S, Shaiova L, et al. L‐carnitine supplementation for the treatment of fatigue and depressed mood in cancer patients with carnitine deficiency: a preliminary analysis. Annals of the New York Academy of Sciences 2004;1033:168‐76. - PubMed
Ellaway 1999 {published data only}
    1. Ellaway CJ, Peat J, Williams K, Leonard H, Christodoulou J. Rett syndrome: randomized controlled trial of L‐carnitine. Journal of Child Neurology 1999;14(3):162‐7. - PubMed
Gillingham 2003 {published data only}
    1. Gillingham MB, Connor WE, Matern D, Rinaldo P, Burlingame T, Meeuws K, et al. Optimal dietary therapy of long‐chain 3‐hydroxyacyl‐CoA dehydrogenase deficiency. Molecular Genetics & Metabolism 2003;79(2):114‐23. - PMC - PubMed
Goa 1987 {published data only}
    1. Goa KL, Brogden RN. l‐Carnitine. A preliminary review of its pharmacokinetics, and its therapeutic use in ischaemic cardiac disease and primary and secondary carnitine deficiencies in relationship to its role in fatty acid metabolism. Drugs 1987;34(1):1‐24. - PubMed
Huidekoper 2006 {published data only}
    1. Huidekoper HH, Schneider J, Westphal T, Vaz FM, Duran M, Wijburg FA. Prolonged moderate‐intensity exercise without and with L‐carnitine supplementation in patients with MCAD deficiency. Journal of Inherited Metabolic Disease 2006;29(5):631‐6. - PubMed
Igarashi 1990 {published data only}
    1. Igarashi N, Sato T, Kyouya S. Secondary carnitine deficiency in handicapped patients receiving valproic acid and/or elemental diet. Acta Paediatrica Japonica 1990;32(2):139‐45. - PubMed
Kelley 1994 {published data only}
    1. Kelley RI. The role of carnitine supplementation in valproic acid therapy. Pediatrics 1994;93(6):1174‐5. - PubMed
Kolker 2004 {published data only}
    1. Kolker S, Burgard P, Okun JG, Schulze‐Bergkamen A, Assmann B, Greenberg CR, et al. Looking forward‐an evidence‐based approach to glutaryl‐CoA dehydrogenase deficiency. Journal of Inherited Metabolic Disease 2004;27(6):921‐6. - PubMed
Krähenbühl 1995 {published data only}
    1. Krähenbühl S. [Carnitine: vitamin or doping?]. Therapeutische Umschau 1995;52(10):687‐92. - PubMed
Lee 2005 {published data only}
    1. Lee PJ, Harrison EL, Jones MG, Jones S, Leonard JV, Chalmers RA. L‐carnitine and exercise tolerance in medium‐chain acyl‐coenzyme A dehydrogenase (MCAD) deficiency: a pilot study. Journal of Inherited Metabolic Disease 2005;28(2):141‐52. - PubMed
Maebashi 1978 {published data only}
    1. Maebashi M, Kawamura N, Sato M, Imamura A, Yoshinaga K. Lipid‐lowering effect of carnitine in patients with type‐IV hyperlipoproteinaemia. Lancet 1978;2(8094):805‐7. - PubMed
Mayer 1989 {published data only}
    1. Mayer G, Graf H, Legenstein E, Linhart L, Auer B, Lohninger A. L‐carnitine substitution in patients on chronic hemodialysis. Nephron 1989;52(4):295‐9. - PubMed
Morris 1998 {published data only}
    1. Morris AA, Turnbull DM. Fatty acid oxidation defects in muscle [abstract]. Current Opinion in Neurology 1998;11(5):485‐90. - PubMed
Muller 2004 {published data only}
    1. Muller E, Kolker S. Reduction of lysine intake while avoiding malnutrition‐‐major goals and major problems in dietary treatment of glutaryl‐CoA dehydrogenase deficiency. Journal of Inherited Metabolic Disease 2004;27(6):903‐10. - PubMed
Schmidt‐S 1983 {published data only}
    1. Schmidt‐Sommerfeld E, Penn D, Wolf H. Carnitine deficiency in premature infants receiving total parenteral nutrition: effect of L‐carnitine supplementation. Journal of Pediatrics 1983;102(6):931‐5. - PubMed
Schulpis 1990 {published data only}
    1. Schulpis KH, Nounopoulos C, Scarpalezou A, Bouloukos A, Missiou‐Tsagarakis S. Serum carnitine level in phenylketonuric children under dietary control in Greece. Acta Paediatrica Scandinavica 1990;79(10):930‐4. - PubMed
Sirtori 2000 {published data only}
    1. Sirtori CR, Calabresi L, Ferrara S, Pazzucconi F, Bondioli A, Baldassarre D, et al. L‐carnitine reduces plasma lipoprotein(a) levels in patients with hyper Lp(a). Nutrition, metabolism, and cardiovascular diseases : NMCD 2000;10(5):247‐51. - PubMed
Vilaseca 1993 {published data only}
    1. Vilaseca MA, Briones P, Ferrer I, Campistol J, Riverola A, Castillo P, et al. Controlled diet in phenylketonuria may cause serum carnitine deficiency. Journal of Inherited Metabolic Disease 1993;16(1):101‐4. - PubMed
Winter 2003 {published data only}
    1. Winter SC. Treatment of carnitine deficiency. Journal of Inherited Metabolic Disease 2003;26(2‐3):171‐80. - PubMed
Wolff 1986 {published data only}
    1. Wolff JA, Carroll JE, Phuc Thuy, Prodanos C, Haas R, Nyhan WL. Carnitine reduces fasting ketogenesis in patients with disorders of propionate metabolism. Lancet 1986;1(8476):289‐91. [MEDLINE: ] - PubMed
Yeh 1985 {published data only}
    1. Yeh YY, Cooke RJ, Zee P. Impairment of lipid emulsion metabolism associated with carnitine insufficiency in premature infants. Journal of Pediatric Gastroenterology & Nutrition 1985;4(5):795‐8. - PubMed
Zilleruelo 1989 {published data only}
    1. Zilleruelo G, Novak M, Hsia SL, Goldberg R, Abitbol C, Monkus E, et al. Effect of dialysate composition on the lipid response to L‐carnitine supplementation. Kidney International ‐ Supplement 1989;27:S259‐63. - PubMed

References to studies awaiting assessment

Rodriguez 1997 {published data only}
    1. Rodriguez DRE, Mendible A, Gomez N, Williams P, Meneses P, Mathison Y. Drug intervention program in dyslipemic children: Use of L‐carnitine. Revista Latina De Cardiologia ‐ Euroamericana 1997;18(2):25‐30.

Additional references

Brown 2006
    1. Brown P, Brunnhuber K, Chalkidou K, Chalmers I, Clarke M, Fenton M, et al. How to formulate research recommendations. BMJ 2006;333(7572):804‐6. - PMC - PubMed
Cairns 2000
    1. Cairns PA, Stalker DJ. Carnitine supplementation of parenterally fed neonates. Cochrane Database of Systematic Reviews 2000, Issue 4. [DOI: 10.1002/14651858.CD000950] - DOI - PMC - PubMed
Chakrapani 2001
    1. Chakrapani A, Cleary MA, Wraith JE. Detection of inborn errors of metabolism in the newborn. Archives of Disease in Childhood. Fetal and Neonatal Edition 2001;84(3):F205‐10. - PMC - PubMed
Egger 1997
    1. Egger M, Davey‐Smith G, Schneider M, Minder C. Bias in meta‐analysis detected by a simple, graphical test. BMJ 1997;315(7109):629‐34. - PMC - PubMed
Elbourne 2002
    1. Elbourne D, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A. Meta‐analysis involving cross‐over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140‐9. - PubMed
Evangeliou 2003
    1. Evangeliou A, Vlassopoulos D. Carnitine metabolism and deficit‐‐when supplementation is necessary?. Current Pharmaceutical Biotechnology 2003;4(3):211‐9. - PubMed
Higgins 2003
    1. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327(7414):557‐60. - PMC - PubMed
Higgins 2011a
    1. Higgins JPT, Altman DG (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Higgins 2011b
    1. Higgins JPT, Deeks JJ, Altman DG on behalf of the CSMG. Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Itoh 1996
    1. Itoh T, Ito T, Ohba S, Sugiyama N, Mizuguchi K, Yamaguchi S, et al. Effect of carnitine administration on glycine metabolism in patients with isovaleric acidemia: significance of acetylcarnitine determination to estimate the proper carnitine dose. Tohoku Journal of Experimental Medicine 1996;179(2):101‐9. - PubMed
Kolker 2006
    1. Kölker S, Garbade SF, Greenberg CR, Leonard JV, Saudubray JM, Ribes A, et al. Natural history, outcome, and treatment efficacy in children and adults with glutaryl‐CoA dehydrogenase deficiency. Pediatric Research 2006;59(6):840‐7. - PubMed
Kolker 2007
    1. Kolker S, Christensen E, Leonard JV, Greenberg CR, Burlina AB, Burlina AP, et al. Guideline for the diagnosis and management of glutaryl‐CoA dehydrogenase deficiency (glutaric aciduria type I). Journal of Inherited Metabolic Disorders 2007;30(1):5‐22. - PubMed
Kruer 2008
    1. Kruer MC, Steiner RD. The role of evidence‐based medicine and clinical trials in rare genetic disorders. Clinical Genetics 2008;74(3):197‐207. - PubMed
Leonard 2006
    1. Leonard JV, Morris AA. Diagnosis and early management of inborn errors of metabolism presenting around the time of birth. Acta Paediatrica 2006;95(1):6‐14. - PubMed
Lepage 2006
    1. Lepage N, Li D, Kavsak PA, Bamforth F, Callahan J, Dooley K, et al. Incomplete pediatric reference intervals for the management of patients with inborn errors of metabolism. Clinical Biochemistry 2006;39(6):595‐9. - PubMed
Pollitt 1997
    1. Pollitt RJ, Green A, McCabe CJ, Booth A, Cooper NJ, Leonard JV, et al. Neonatal screening for inborn errors of metabolism: cost, yield and outcome. Health Technology Assessment 1997;1(7):1‐202. - PubMed
Poustie 2010
    1. Poustie VJ, Wildgoose J. Dietary interventions for phenylketonuria. Cochrane Database of Systematic Reviews 2010, Issue 1. [DOI: 10.1002/14651858.CD001304.pub2] - DOI - PMC - PubMed
RevMan 2011 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
Seymour 1997
    1. Seymour CA, Thomason MJ, Chalmers RA, Addison GM, Bain MD, Cockburn F, et al. Newborn screening for inborn errors of metabolism: a systematic review. Health Technology Assessment 1997;1(11):1‐95. - PubMed
Steiner 2005
    1. Steiner RD. Evidence based medicine in inborn errors of metabolism: is there any and how to find it. American Journal of Medical Genetics 2005;134A(2):192‐7. - PubMed
Walter 2003
    1. Walter JH. L‐Carnitine in inborn errors of metabolism: What is the evidence?. Journal of Inherited Metabolic Disease 2003;26(2‐3):181‐8. - PubMed
Webster 2010
    1. Webster D, Wildgoose J. Tyrosine supplementation for phenylketonuria. Cochrane Database of Systematic Reviews 2010, Issue 8. [DOI: 10.1002/14651858.CD001507.pub2] - DOI - PubMed
Wilcken 2003
    1. Wilcken B, Wiley V, Hammond J, Carpenter K. Screening newborns for inborn errors of metabolism by tandem mass spectrometry. New England Journal of Medicine 2003;348(23):2304‐12. - PubMed
Winter 1998
    1. Winter SC, Buist NRM. Inborn errors of Metabolism: Medical and Administrative "Orphans". American Journal of Managed Care 1998;4(8):1164‐8. - PubMed
Yi 2008
    1. Yi SHL, Singh RH. Protein substitute for children and adults with phenylketonuria. Cochrane Database of Systematic Reviews 2008, Issue 4. [DOI: 10.1002/14651858.CD004731.pub3] - DOI - PubMed

Publication types

MeSH terms